Pages

Showing posts with label Mission Monday. Show all posts
Showing posts with label Mission Monday. Show all posts

Monday, March 10, 2014

Mission Monday: Cancer Survivor Conquers Mt. Everest

With only one functioning lung, a prognosis of fourteen days to live, and being in a medically-induced coma for a year, Sean Swarner is the first cancer survivor to stand on top of the world…Mt. Everest.  Sean has broken through defined human limitation in order to redefine the way the world views success.
Sean was diagnosed with two deadly, different, and unrelated forms of cancer, once at the age of thirteen and again at the age of sixteen. After an incredibly poor prognosis, and being read his last rites, Sean astounded the medical community when he survived both these brutal diseases. He realized that after defeating cancer twice, no challenge would ever be too great, no peak too high.
Sean proved his theory when he crested the peak of Mt. Everest. As the first cancer survivor to do so, Sean decided to continue climbing and has since topped the highest peaks in Africa, Europe, South America, Australia, Antarctica, and North America, thus completing the “7-Summits”.
With the completion of the Ironman World Championship in Hawaii, Sean has his sights on trekking to the Poles at the top and bottom of the world.  This will designate Sean as the first person ever to complete what is known as the “Ultimate Grand Slam“.
As Sean continues to defy the odds, test his own endurance and inspire and motivate people around the world, he carries his message of healing, hope, and triumph with cancer patients worldwide. Read more of his story here

Monday, January 6, 2014

Mission Monday: Texas Researcher Wins Major LLS Grant



The Leukemia & Lymphoma Society (LLS) today announced it has awarded four new grants through its prestigious Marshall A. Lichtman Specialized Center of Research (SCOR) research initiative, bringing the program's total funding to $285 million since its inception in 2000.

Helen E. Heslop, MD, at Baylor College of Medicine in Houston, TX is one of four recipients of this grant. Heslop and her team of 11 colleagues at Baylor College of Medicine, Houston, will expand upon previous success in mobilizing the immune system to control blood cancers by attempting to define safer, simpler, and more effective immunotherapies for the treatment of acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). They will investigate if naturally occurring "off the shelf" cytotoxic T lymphocytes (CTLs), also known as killer T cells, can be as effective under some circumstances as engineered T cells against lymphoma. In addition, they will devise ways to augment the effectiveness of CTLs in MM and optimize strategies to isolate and expand CTLs against ALL. This research is significant because immunotherapies may produce better responses in patients compared with existing therapies. Beyond that, there is a need to reduce the complexity and cost in order to make such therapy accessible to more patients. 

The innovative SCOR program funds teams of researchers representing different disciplines and engaged in collaborative efforts to discover new approaches to treat patients with blood cancers. Each team will each receive $1.25 million a year for five years, for a total of $6.25 million. 


Monday, December 30, 2013

Mission Monday: January Education Programs



When a patient is diagnosed with a blood cancer their life changes dramatically in an instant.  It is not only their life that changes, but that of their family and friends.  The Leukemia & Lymphoma Society (LLS) understands and appreciates that a blood cancer patient does not tackle their diagnosis alone.  For that reason, LLS has created a series of different telephone and web education programs for patients and their support group that will help them along the rocky road to remission.

Below are two educational phone and web education programs that are FREE and available to you.  Please take advantage of this opportunity to learn more about ALL and Myeloma.

Adult Acute Lymphoblastic Leukemia (ALL)
Tuesday, January 14, 2014 from 1:00 to 2:30 pm (ET)
Dan Douer, MD, Memorial Sloan Kettering Cancer Center

Myeloma- Update on Research and Treatment
Tuesday, January 21, 2014 from 1:00 to 2:30 pm (ET)
Robert Orlowski, MD, PhD, MD Anderson Cancer Center



Monday, December 23, 2013

Mission Monday: Gingerbread House Fundraiser


In San Francisco, CA a little boy named Rhett created a spectacular gingerbread house in The Fairmont Hotel to raise money and awareness of The Leukemia & Lymphoma Society and blood cancers.  In front of this life-size gingerbread house he posted this note:

My name is Rhett.  My sister's name is Annesley.
Happy Holidays and Welcome to the Fairmont Hotel Gingerbread House.
Leukemia is cancer in my blood
Cancer cells are the bad guys.
I take chemo to get the bad guys out.
Thank you for raising money to help get the bad guys out.
Someday we will all say GONE WITH THE CANCER
My name is Rhett and I GIVE A DAMN


We are thankful for volunteers of all ages who work tirelessly to further the LLS mission to create a world without blood cancers.


Happy Holidays from North Texas!

Monday, December 2, 2013

Mission Monday: Advocate for Children


Each year, 13,500 children are diagnosed with cancer. We can help them.

The Gabriella Miller Kids First Research Act of 2013 would take the revenue from the Presidential Election Campaign Fund and reassign it to the National Institute of Health to improve treatments for childhood cancer, diabetes, and many other pediatric diseases.

We need 200 co-sponsors to make this bill a reality – CLICK HERE see where your Representative stands and send your message below:

"As an advocate with The Leukemia & Lymphoma Society, I want to thank you for signing on as a co-sponsor of H.R. 2019, the Gabriella Miller Kids First Research Act. 

Each year, over 140,000 Americans are newly diagnosed with blood cancers, accounting for nearly 10 percent of all newly diagnosed cancers in the United States. Among them are more than 13,500 children who will face cancer in the coming year -- far too many, especially when we can do something to help them.

That’s why I’m writing to you today to thank you for co-sponsoring the Kids First Research Act of 2013, which will increase funding for pediatric medical research activities administered through the Common Fund at the National Institutes of Health. By turning off the Presidential Election Campaign Fund and instead designating this revenue to expand pediatric disease research, we can get closer to a cure for blood cancers and for many other childhood diseases, all within the current budget.

Thanks again for supporting H.R. 2019."

Thank you for helping us create a world without blood cancers.

Monday, November 4, 2013

Mission Monday: Champion of Coverage


The Leukemia & Lymphoma Society (LLS) has been selected as a "Champion of Coverage" by the Centers for Medicare & Medicaid Services (CMS).  LLS joined more than 100 national organizations and businesses that have volunteered to help Americans learn about the health care coverage available in a non-partisan manner.

Our goal is to ensure that blood cancer patients and their families have the information needed to make an informed decision about purchasing health care coverage.  In order to do this, LLS has created a dedicated section on the website, www.LLS.org/ACA, which provides helpful information and links to useful tools, such as the cancer insurance checklist that LLS helped to develop.  The LLS Information Resource Center is also available to answer questions Monday - Friday from 9a.m. - 6p.m. at (800) 955-4572.

LLS continues to pursue opportunities that provide greater access to information and resources for blood cancer patients.

Monday, October 21, 2013

Mission Monday: Meet an LLS-Funded Research in Texas

Dr. Larry Kwak
The Leukemia & Lymphoma Society (LLS) spends millions of dollars every year supporting the work of the best and brightest blood cancer researchers around the world.

Today we introduce you to Larry Kwak, M.D., Ph.D. of the University of Texas M.D. Anderson Cancer Center. Dr. Kwak's work has been sponsored by LLS since 2011. His focus is in two on two areas: lymphoma and myeloma.  Below he describes his current projects that are showing great promise. 

"B cells are a type of white blood cell (called a B lymphocyte) that produces antibodies to identify and neutralize invading pathogens such as bacteria and viruses. The human body has the ability to form millions of different types of B cells each day, and each type has a unique receptor protein (referred to as the B-cell receptor, BCR) on its membrane that will bind to one particular antigen. However B cells can become a tumor just like any other cell. B-cell tumors are known as non-Hodgkin lymphoma (NHL). In this project we will focus on mantle cell lymphoma (MCL), which is one of the rarest of the NHLs and currently has the worst prognosis of all malignant lymphomas. MCL has also own unique antigen receptors. However, we do not know what antigen is recognized by BCR and what the antigen plays a critical role in the biology and clinical outcome of MCL. We believe that B cells chronically stimulated by antigen through their B-cell receptor is one mechanism for causing MCL. The objective of this proposal is to identify the nature of the proteins that bind and provide signals to the MCL through their B-cell receptor. Furthermore, we will study the biological role of B-cell receptor by using patient tumor in a humanized mouse model. Finally, we will analyze the relationship between molecular features of the BCR/antigen and clinical outcomes. We are particularly well prepared to undertake the proposed research, because we have identified candidate antigens. Our preliminary data suggesting that a self-antigen (unlike bacteria and viruses) could be a potential antigen. Second, we have created a unique humanized mouse model system for primary MCL. It is a mouse model that has biologically functioning patient MCL cells that are transplanted. This is the first human primary MCL animal model and should be useful for the biological and therapeutic research of patient MCL cells. Finally, we have a well-established tissue bank and clinical database which characterizes long-term clinical outcome data on each patient in the Department of Lymphoma/Myeloma at M. D. Anderson Cancer Center. Successful completion of these studies will result in better understanding of the biological and clinical role of the BCR in this disease. This information will be utilized in the development of novel strategies for identifying prognosis markers and for treatment of these lymphomas."

Monday, October 7, 2013

Mission Monday: Meet a LLS-Funded Researcher in Texas

Helen Heslop, M.D.
The Leukemia & Lymphoma Society (LLS) spends millions of dollars every year supporting the work of the best and brightest blood cancer researchers around the world.

Today we introduce you to Helen Heslop, M.D. of Baylor College of Medicine in Houston.  Dr. Heslop's work has been sponsored by LLS since 2009. Her focus is on manipulating cells to keep them from becoming resistant to anticancer drugs and below she describes a current joint project that is showing great promise.
"Chemotherapy for lymphoma often cures the disease, but the intensive drug treatments that destroy lymphoma cells also kill normal cells, resulting in serious side effects. Another problem with standard treatment is that the lymphoma cells can become resistant to one or more of the anticancer drugs, so that the disease can come back. One way to avoid these complications is to use the patient’s own immunity to target lymphoma cells while sparing healthy tissues and organs. Investigators in the Center for Cell and Gene Therapy at Baylor College of Medicine have found that a particular kind of immune cell called the cytotoxic T lymphocytes, or CTLs - can be manipuiated to effectively treat for some types of lymphoma related to the Epstein-Barr virus (EBV). They now plan to modify their successful treatment strategies so that they will apply to patients with other types of lymphoma. Drs Cliona Rooney and Helen Heslop will improve treatments for the types of Hodgkin and other lymphomas associated with EBV by re-focusing the CTLs onto two EBV-derived structures on the tumor cell surface. They will also give patients an antibody that will remove many of the cells and molecules that stop the CTLs working at tumor sites. They will also engineer the CTLs cells so that they will become able to recognize a structure that is present on the tumor cells of almost all patients with Hodgkin lymphoma, not just those whose disease is associated with EBV. This approach is based on studies by Dr Malcolm Brenner, who has shown that CTLs for lymphoma can be redirected to tumors by changing the targeting-molecules they express on their surface. Dr Brenner will test this approach in lymphoma patients whose cells express a structure called CD19. He will also test the idea that changing other CTL surface molecules will allow cells to evade the body`s defenses against self-directed immune responses and kill larger numbers of lymphoma cells. Finally, Dr Si-Yi Chen has discovered that the action of an unusual protein called suppressor of cytokine signaling 1 (SOCS1) can be switched-off to allow a different type of immune cell called a dendritic cell to provide stronger stimulation of CTLs. If switching-off SOCS1 improves CTL killing of lymphoma cells in mice, this strategy will be tested in patients, by giving a dendritic cell vaccine. These investigators are creating a collaborative research environment that will yield better results that would be expected from a single laboratory working in isolation. Their long-term goal is to advance cure rates in Hodgkin and non-Hodgkin Iymphomas without the side effects typically seen with conventional treatments, and ultimately to extend the benefits of CTL therapy to other blood cancers."

Monday, September 23, 2013

Mission Monday: LLS Information Specialists



The Leukemia & Lymphoma Society (LLS)  offers a number of services free of charge for blood cancer patients, their families and caregivers.  Today the focus is on LLS Information Specialists and how they can play a significant role in helping a newly diagnosed person understand their treatment options.

Our Information Specialists are master's level social workers and health educators who can help people with cancer navigate through treatment, financial and social challenges and give accurate, up-to-date disease and treatment information.

Below is a list of some of the major issues they can help you address:
  • help you deal with the challenges of your diagnosis
  • provide information about treatment options
  • help you map the best route from diagnosis through treatment and survivorship
  • conduct individual clinical trial searches for you and help you develop a list of questions to ask your doctor about participating in a clinical trial
  • help you communicate with members of your healthcare team
  • connect you to national resources
  • connect you with the patient services manager at your local chapter who can guide you to local programs and resources
  • provide you with free materials to help you on your cancer journey
Callers may request the services of a language interpreter. Medical interpretation services are available in 170 languages.  For automated translation assistance, go to web page translation. This automated tool can provide only a general translation of the page.

Reach out to an Information Specialist in one of the following ways:
  • Call (800) 955-4572, Monday to Friday, 9 a.m. to 6 p.m. ET, for support and guidance.
  • Leave a message for a call back 24/7. Use the automated response system 24 hours a day, seven days a week. Call (800) 955-4572. An Information Specialist will return your call the next business day. You can also listen to recorded information about LLS and our programs.
  • Visit Live Patient Help to chat with a specialist online, Monday to Friday, 10 a.m. to 5 p.m. ET.
  • Email your inquiries to infocenter@LLS org. All email messages are answered within one business day.

Monday, September 16, 2013

Mission Monday: Meet an LLS-funded Researcher in Texas


Kala Kamdar, M.D.
The Leukemia & Lymphoma Society (LLS) spends millions of dollars every year supporting the work of the best and brightest blood cancer researchers around the world.

Today we introduce you to Kala Kamdar, M.D. from Baylor College of Medicine in Houston.  Dr. Kamdar's work has been sponsored by LLS since 2011. Her focus has been on acute lymphoblastic leukemia (ALL) and the long term effects of current cancer treatments.  Below she describes her current project that is showing great promise.

"Acute lymphoblastic leukemia (ALL) is the most common cancer in childhood. Remarkable advances in therapy have resulted in a cure rate of approximately 80%. However, many long-term survivors of childhood ALL face chronic health problems related to exposure to chemotherapy and radiation at a young age. Specifically, long-term survivors of ALL are at an increased risk for excessive weight gain and heart disease, compared to the general population. It is not clear why some long-term survivors of childhood ALL are at a higher risk for obesity than other survivors who received the same treatment. Genetic differences may explain why some children respond differently to certain treatments than others, both in terms of effectiveness and side effects of therapy. We propose that some children may have genetic susceptibility to obesity after receiving chemotherapy and cranial irradiation for ALL. We will examine the role of genetic variation in the development of treatment-related obesity in 1,200 long-term survivors of childhood ALL enrolled in the Childhood Cancer Survivor Study. We will investigate whether differences in the genetic make-up of these survivors can predict why some children develop overweight/obesity (BMI 25) after ALL treatment whereas others do not. We will also evaluate whether gender, age, and ALL treatment differences influence the relationship between genetics and obesity. Our findings from this first study will be validated in an independent study of 400 ALL survivors who are followed at Texas Children’s Hospital. If we can identify which children with ALL are at risk for excessive weight gain based on genetics, we may develop early interventions to prevent this important side effect of therapy and optimize the lifelong health of these children."

Monday, September 9, 2013

Mission Monday: Patient Financial Aid


The Leukemia & Lymphoma Society (LLS)  offers a number of services free of charge for blood cancer patients, their families and caregivers.  Today the focus is on the different patient financial aid programs LLS offers patients.


A limited amount of financial assistance is available to help patients with significant financial need and who are under a doctor's care for a confirmed blood cancer diagnosis. This program is supported entirely by public contributions and patient aid funds are subject to availability.

To find out if you are eligible for the LLS Co-Pay Assistance Program, you will need to contact LLS.  For eligible patients, the Co-Pay Assistance Program may offer a larger amount of financial support for select diseases toward the cost of insurance co-payments and/or insurance premium costs for prescription drugs. Please visit the Co-pay Assistance Program for more information or to apply.

The Patient Financial Aid Program provides $100 a year to help patients offset expenses. Receipts for expenses are not required. To apply, you must be a US resident or US military personnel stationed abroad and in active treatment or ongoing medical follow-up care for a blood cancer. Your prescribing healthcare provider must complete and sign the bottom portion of the application form.  The program begins each July 1st and ends on the following June 30th. You must reapply every year after June 30th in order to receive assistance.

How to Apply:

Contact the North Texas Chapter at (972) 996-5900 to request an application
or Print, complete and return the online application: (color or black and white) to your chapter.

For more information about the Patient Financial Aid program, contact the North Texas Chapter.
For information and an application in Spanish, click here.

Monday, July 29, 2013

Mission Monday: LLS Featured as Leader in Venture Philanthropy and Sceince



In April, The Leukemia & Lymphoma Society (LLS) was invited to participate in the 2013 Milken Institute Global Conference, where some of the world's most extraordinary people gather to explore solutions to today's most pressing challenges in business, health, government, and education. Speakers included former British Prime Minister Tony Blair, former Vice President Al Gore, Microsoft's Bill Gates, Mexican business magnate Carlos Slim, Senator Harry Reid (D-NV) and Rep. Eric Cantor (R-VA).

Louis DeGennaro, PhD, LLS Chief Mission Officer, joined venture capitalists, pharmaceutical and biotech executives and board members from Faster Cures at three different panel discussions to explore funding options for advancing innovative research. He participated in discussions about why high risk long-term investments are needed to turn medical innovation into new therapies, the two different pathways within the LLS Therapy Acceleration Program, and funding options to support cutting-edge research.

Many participants at the conference expressed their appreciation and support for LLS research. Executive director of Faster Cures Margaret Anderson said, "LLS has been transforming the blood cancer space," while NIH Director Dr Francis Collins conveyed a similar sentiment, "LLS is doing great science. We are so proud of our National Center for Advancing Translational Science partnership with you."

Monday, July 22, 2013

Mission Monday: Specialist Thompson



On June 9, 2013 U.S. Army Specialist Warren Thompson completed the Wounded Warrior Half Marathon in Irving as a summer participant with Team In Training (TNT).  Warren is a familiar face to many TNT participants in North Texas, as he was a marathon coach for several years prior to enlisting in the Army in the fall of 2011 to become a combat medic.  In January Warren reunited with TNT, but this time as a participant.  Throughout the summer season (when he didn’t have Army commitments), he made the almost-three-hour commute from Fort Hood in Killeen, where he’s currently stationed, to Grapevine to join his North West Cities teammates for Saturday morning trainings.  Not only that, he trained for the race wearing his 45-pound Army rucksack to honor his fellow military service members and those wounded in action.  On race day, Warren represented the Army and TNT well – wearing both his fatigues and his purple race jersey (and his heavy rucksack)!  We congratulate Warren on a successful race and season with TNT, and extend our sincere gratitude to Specialist Thompson for his service to our country.

Monday, July 8, 2013

Mission Monday: Bruce Cleland at 25th Anniversary Gala

Bruce Cleland (center) with North Texas Team In Training staff
and Team In Training Vice President Chris Fenton (far right)
at the Team In Training 25th Anniversary Gala on June 30, 2013.

When Team In Training (TNT) founder Bruce Cleland visited North Texas for the Team In Training 25th Anniversary Gala, he told the inspiring story of how he and a group of friends created the groundbreaking charity training program in 1988.  He also shared a number of personal photographs with Gala attendees.


Bruce introduced the Gala crowd to his motivation: his young daughter, Georgia.  She was diagnosed with leukemia when she was just two years old. 

Bruce shared the picture above of Georgia during her tough treatment with her doll, which she named Dolly.  When diagnosed, her chances of surviving were 50-50.  Fortunately for the Cleland family, Georgia would be a success story


After Georgia's treatment, Bruce decided to fundraise for The Leukemia & Lymphoma Society (then The Leukemia Society of America) by recruiting a group of individuals to run in the New York City Marathon.  He set out on a recruiting process of finding not only runners but also corporate backers to fund their effort.  The picture above is the first Team In Training team ever formed.  The picture was taken after one of their first training runs.

After months of training and fundraising, all 38 members of the first Team In Training team crossed the finish line of the New York City Marathon.  The group raised $320,000 for The Leukemia & Lymphoma Society and blood cancer research and created a world-wide phenomenon of endurance charity training programs.



Above is a picture of Bruce finishing the New York City Marathon in honor of Georgia.  The bright tights, a gift from the team inagural TNT team the night before the race, are still around and making appearances.



They spent much of the night of the North Texas Team In Training 25th Anniversary Gala tied around his neck like a cape.



And Georgia Cleland?  She is following in her father's very famous footsteps and helping to raise money for other blood cancer patients.  Georgia, now 28, finished her first TNT event in 2012 and is currently training for the San Francisco Women's Marathon this October.

Monday, June 17, 2013

Mission Monday: Mantle Cell Lymphoma Information Session

Mantle Cell Lymphoma:
Understanding Your Treatment Options

Join us for a FREE Telephone/Web Education Program
The latest information for patients, caregivers and healthcare professionals

DATE:
Wednesday, June 26, 2013

TIME:
12:00p.m. - 1:00p.m. CST

SPEAKER:
John P. Leonard, MD
The Richard T. Silver Distinguished
      Professor of Hematology and Medical Oncology
Weill Cornell Medical College
New York, NY

Ask Dr. Leonard a question during the Q&A session.




WE INVITE YOU TO LEARN MORE ABOUT:
  • Characteristics of mantle cell lymphoma (MCL)
  • Current and emerging therapies for MCL
  • The role of clinical trials in the advancement of MCL treatments for patients
  • Importance of patient-provider communications in treatment side effects and management
To register by phone, please call (877) 264-4949, ext 2 or visit www.lls.org/programs

Continuing education for nurses and social workers, please visit www.lls.org/professionaled

This educational call is supported by grants from Celgene Corporation and Milennium: The Takeda Oncology Company.

Monday, June 10, 2013

Mission Monday: First Connection Volunteer

Bill Bock with Deputy Executive Director Stacey Russell (left)
and Executive Director Patricia Thomson (right) at the 2013
Volunteer Appreciation Event.

I will always remember the moment when the doctor said "I’m afraid you have AML and it is a very serious form of leukemia". He explained that this disease was highly complex and that his hospital did not even take AML patients. In a blur, we were shuffled off to a larger facility where a new oncologist spent a goodly amount of time with treatment options and ended by saying I needed to be admitted immediately. We left with a whirlwind of terms like chemically induced remission, stem cell transplant, graft vs. host disease and many other barely understood concepts. The whole ordeal was frightening and I wept when I told my children.

The hospital stay was long and emotionally exhausting for my family. In 2005 patients were confined to one floor in an effort to avoid outside infections. I recall praying for simple things like sunshine and a light breeze on my face as I watched runners twelve stories below and wishing I could join them. Upon remission, my transplant nurse said she had found a number of potential donors and that two were considered perfect matches. Furthermore, each agreed to donate. After undergoing a second high level chemotherapy round to prepare my body for the transplant, the actual transplant process was almost anticlimactic.

The roller coaster of emotions eventually came to an end and I was released to begin the healing process.

In subsequent doctor visits I learned of The Leukemia Lymphoma Society (LLS)and their First Connection program and it brought back all those feelings of fear and despair. My wife and I would have loved to speak to a survivor who had experienced all this. I told myself I would get involved so that someday a man just like me would learn that this is not a death sentence and that there can be a positive outcome.

Five years and three more grandchildren later, I was pronounced cured.

Since then I have signed on as a First Connection volunteer for the North Texas Chapter and have made countless calls to newly diagnosed patients of all blood cancers. While attempting to alleviate their fears, I also make them aware of other LLS services that can help with financial, psychological and legal difficulties.


About the First Connection Program:
The Patti Robinson Kaufmann First Connection Program is a free service of LLS that enables patients and their loved ones to connect with a trained peer volunteer who has gone through a similar experience.  The program makes an average of 6,000 first connections each year.

LLS First Connection peer volunteers are in a unique position to provide support and community resource information to others facing a similar cancer diagnosis.  Patients and their family members are matched with peer volunteers.  The match is based on diagnosis, age, gender and other factors that might create a mutual understanding and ease of communication between participants and volunteers.

You can learn more here about how to take advantage of the First Connection Program in North Texas as either a volunteer or recipient.

Monday, June 3, 2013

Mission Monday: Mission Day



This year's Federal Mission Day is here, with advocates scheduled to arrive in Washington, D.C. today for training and to take the Capitol by storm on June 4th. This dynamic meeting partners Executive Directors, Patient Services staff, and engaged volunteers with The Leukemia & Lymphoma Society's (LLS) Office of Public Policy, working together to help accelerate new cures and treatments for our patients and ensure they have access to quality, coordinated cancer care. This meeting will bring together the three pillars of the LLS mission: research, patient services, and advocacy, to drive better public policies that will help our patients live better, longer lives.

If you didn't make the trip to Washington, DC this year, you can still help participate in our efforts to educate Congress about the need to find a cure for blood cancers.    Add your name to the Mission Day petition today to let your members of Congress know that blood cancer patients are counting on them to support research and treatment options to help patients live longer, better lives - not someday, but today.

SIGN the Mission Day petition now and send out to your network of family and friends to do the same.

Monday, May 27, 2013

Mission Monday: Brian Druker, M.D.



For more than sixty years, The Leukemia & Lymphoma Society (LLS) has supported groundbreaking and lifesaving research.  One of the most notable researchers LLS has supported is Brian Druker, M.D.  He was a leader during the 1990s in the development of Gleevec, a revolutionary "targeted therapy" approved by the FDA in 2001 for patients with chronic myeloid leukemia.  Recent studies show that more than 90% of nearly diagnosed early stage chronic myeloid leukemia patients can expect to survive long-term.  Dr. Druker is a large reason why that number is so high. 

Watch this video to find out what piqued Dr. Druker's interest in blood cancers early in his career.

Monday, April 29, 2013

$100,000 and Still Going Strong


Claire Oliver has been involved with Team in Training since 2003. She was connected with the Society after the passing of her stepfather, Tom Hillary in 2000. 

Claire has worked with LLS as a TNT coach and fundraising participant every year since. Claire has completed 17 fundraising events with the North Texas Chapter, and is currently raising money for America's Most Beautiful Bike Ride in Lake Tahoe. This event will complete her 4th Triple Crown Award. She has raised over $100,000 for LLS in the last 10 years!  

Although Claire only had one connection to the Society and the disease, she has seen the impact of the work of the Leukemia and Lymphoma Society and the difference it makes in the lives of people and families facing blood cancers. Every time Claire thinks she might be competing in her last Team in Training event a new story, patient or family becomes apparent and the fact that there is no cure encourages her to compete one more time.

Claire is relentless for a cure. The difference that is made in the lives of patients and their families pales in comparison to the difference Team in Training has made in her own life. 

Monday, April 15, 2013

Mission Monday: Why I Train - Joy Hunkins

Joy Hunkins is a TNT Coach and she trains in memory of her husband, John.
My first connection with The Leukemia & Lymphoma Society was on June13, 2001.  We were living in Indiana when my husband John, was diagnosed with Acute Myelogenous Leukemia.  He was very ill at the time of his diagnosis.   Our daughter, Lauren, 11 years old at the time was in Florida at Space Camp and after dropping her at camp I stayed in the state, not wanting to be to far from her in case of an emergency.  John was an airline pilot and had been feeling overly tired for some time but had been flying a lot of extra hours getting ready to go on vacation on June 15th.  He was scheduled to meet us in Titusville for Lauren’s graduation from Space Camp.  Instead, he was taken by ambulance to Columbus Regional Hospital where they made his diagnosis.
The ER doctor called my cell phone in Florida to inform me that John had leukemia and that I needed to return to Indiana as soon as possible.  This was on a Wednesday.  I picked Lauren up at camp and we were back in Indiana by noon on Thursday.  The oncology doctor in Columbus gave us our options for locations for treatments.  We chose St. Francis Hospital in Indianapolis.  It was close enough to our home that I could drive to the hospital daily and Lauren would be able to come and see her dad as often as she would like.  John was taken by ambulance that afternoon and was in surgery for his port so his chemotherapy could be administered.  I met with John’s doctors and received so much information that I was completely overwhelmed. 

I had barely even heard of leukemia and what I had heard was that it was mostly a disease that affected children.  So, how could my 54 year old husband have this?  The doctors had to be wrong.  I had so much to learn and had no idea where to start. While John was in surgery a representative from the Leukemia & Lymphoma Society came by his room.  I’m sure it was a patient services representative.  She basically told me that there is a lot of help and support that the Society can offer and reassured me that there was somewhere to turn.  John’s blood counts were so bad when he was taken to the emergency room.   His white count was off the scale in the hundreds of thousands and his red count was at 3.1.  Normal counts for a male are 14 – 17 for red cells and 4,000 – 9,000 for white cells.  His counts were so bad because the leukemia was so acute and was very aggressive.  The doctor later told me that his blood was the consistency of foam, and as you know foam does not circulate through your body very well at all.   His doctors were astounded that he had lived beyond that first day of diagnosis because his leukemia was so advanced but John had a few things yet to do. 

Through treatments made possible by research money from programs like Team in Training, John lived another 6 months losing his battle against leukemia on December 24, 2001.  During these 6 months John spent many weeks in the hospital but also many weeks at home.  While at home he was able to see Lauren make her elementary school’s basketball team, play in games and cheer her on at a few more swim meets.  Most important to Lauren and I was that John had time to write letters to both of us to be opened on important dates in the future.  Like her 13th birthday, my birthday, our 17th wedding anniversary in August, Lauren’s first date, high school & college graduations and on her wedding day.  In his letters John gave Lauren advice that a dad would normally give his daughter in person like how to handle boys on that first date, how to be a good and honorable person, advice that the world was there for her taking and to take full advantage of each and every moment. To never waste a single minute of her life worrying about the unimportant issues.  Always be kind and considerate to herself and to others.    For these 6 months and these precious letters he was able to write to us we thank God first and foremost and secondly the Leukemia and Lymphoma Society for funding the research that enabled his doctors to treat him with aggressive treatments to extend his life while still searching for a cure.

I became involved with Team In Training not long after we moved to Florida.  Lauren, the athlete, was running a 5K and picked up an interest card, having an interest in running as well as the Leukemia & Lymphoma Society being dear to her.  She mailed in the card only to learn that to be a participant for Team In Training you must be 16 years old but she was happy to hear she could help in other ways like volunteering at events. Cheering, passing out water or just helping out.  While she enjoyed helping at events she continued to harass Amy Young, our staff manager for the Central Florida Chapter.  Amy, after being tortured for over a year, explained to Lauren that it was truly out of her power to let her participate but that her mother (me) was certainly old enough.  Can you imagine the look on my face?  Now you need to understand that I was not an athlete, never had been an athlete and really had no desire what so ever to become an athlete.  I could not run down the block let alone a half or full marathon. 

Amy convinced me that I could indeed with the help of the expert coaches from Team In Training walk a half marathon and can you believe it, there was an information meeting the very next night.  The next week I became a proud yet wary participant of Team In Training signed up to the walk the ½ marathon in San Francisco.  Well, you remember I told you that I had completed the full Nike 26.2. in San Francisco.  How did this happen to an absolute non-athlete?   I don’t know if many of you have been to Florida, especially in the summer but it is hot and it is humid.   I figured out pretty soon that running is a much faster way to put in those miles and finish before the sun gets up to high in the sky and the humidity reaches the norm of 100%.  So, I became a runner!  I completed the 2005 Nike 26.2 in 5 hours 32 minutes and 5 seconds.   But you know, as hard as that was for us it is nothing compared to what blood cancer patients go through each and every day.  Treatments are so hard and if we, by running or walking in our ½ or full marathons can help make even one moment of their treatment easier, I’m sure you will agree with me that we will complete as many marathons that it takes until there is a cure.